更新于：2024-06-25
Lipegfilgrastim
利培非格司亭
更新于：2024-06-25
概要
基本信息
非在研机构 |
最高研发阶段批准上市 |
最高研发阶段(中国)- |
特殊审评- |
登录后查看首次获批时间轴
序列信息
Sequence Code 4190
来源: *****
关联
12
项与 利培非格司亭 相关的临床试验LIPEG: A Phase IV, postmarketingstudy of the safety and efficacy of Lipegfigrastim (Lonquex ®) as febrileneutropenia (FN) prophylaxis in patients undergoing chemoimmunotherapy (CIT) for NonHodgkinLymphoma(NHL).
Lonquek (Lipegfilgrastim) for Stem Cell Mobilization of Autologous Hematopoietic Stem Cell Transplantation in Patients With Multiple Myeloma and Lymphoma
An Open-Label, Randomized, Active-Controlled, Multicenter Study to Evaluate the Efficacy, Pharmacokinetics, Pharmacodynamics, Safety, Tolerability, and Immunogenicity of Lipegfilgrastim 100 µg/kg Body Weight in Comparison to Filgrastim 5 µg/kg Body Weight in Pediatric Patients Diagnosed with Ewing Family of Tumors or Rhabdomyosarcoma Receiving Chemotherapy
100 项与 利培非格司亭 相关的临床结果
登录后查看更多信息
100 项与 利培非格司亭 相关的转化医学
登录后查看更多信息
100 项与 利培非格司亭 相关的专利（医药）
登录后查看更多信息
64
项与 利培非格司亭 相关的文献（医药）2023-12-01Cancer control : journal of the Moffitt Cancer Center
Outcome and Cost-Effectiveness Analysis of Long-acting G-CSF as Primary Prophylaxis of Neutropenia Induced by Chemotherapy in Breast Cancer Patients, From a Retrospective Study
Article
作者: Ma, Peizhi ; Zhao, Chenglong ; Jiang, Dandan ; Wang, Yaqin
Purpose:
This retrospective analysis aimed to evaluate the clinical outcomes and cost-effectiveness of long-acting granulocyte-colony stimulating factor as primary prophylaxis of neutropenia caused by chemotherapy for breast cancer.
Methods:
Patients with breast cancer who received long- or short-acting granulocyte-colony stimulating factor as primary prophylaxis of neutropenia were enrolled in this study, and incidences of neutropenia were compared between two groups. A decision-analytic and a Markov model were used to compare the health benefits and costs of utilizing long- vs short-acting granulocyte-colony stimulating factor as the primary prophylaxis from the perspective of the Chinese health service system. Subsequently, one-way deterministic and probabilistic sensitivity analyses were conducted. The incremental cost-effectiveness ratios were calculated in baseline and sensitivity analyses.
Results:
Patients receiving long-acting granulocyte-colony stimulating factor as the primary prophylaxis of chemotherapy-induced neutropenia experienced a significant lower incidence of this adverse event, compared with the short-acting one for 2 to 7 days. The outcomes of baseline analysis indicated that long-acting granulocyte-colony stimulating factor had a gain of 0.08 quality-adjusted life years and costed $149 more than the short-acting one, yielding an incremental cost-effectiveness ratio of $1792 per quality-adjusted life year. The sensitivity analysis proved the stability of our models and economic efficiency of long-acting granulocyte-colony stimulating factor.
Conclusions:
Patients receiving long-acting granulocyte-colony stimulating factor as primary prophylaxis of neutropenia experienced lower risk of this event compared with those underusing short-acting one. The long-acting granulocyte-colony stimulating factor may be a more cost-effective strategy for primary prophylaxis of neutropenia than short-acting one, considering the Chinese willingness-to-pay threshold of $12158.6 per quality-adjusted life year.
2023-11-01Clinical lymphoma, myeloma & leukemia
Loss of CD34+ Cells and Effect of the Number of Viable Cryopreserved CD34+ Cells in the Infused Blood Grafts on Hematologic Recovery, Progression-Free Survival and Overall Survival in NHL Patients After Autologous Stem Cell Transplantation
Article
作者: Pelkonen, Jukka ; Kuitunen, Hanne ; Jantunen, Esa ; Valtola, Jaakko ; Kuittinen, Outi ; Vasala, Kaija ; Turunen, Antti ; Penttilä, Karri ; Partanen, Anu ; Kuittinen, Taru ; Pyörälä, Marja ; Varmavuo, Ville ; Mäntymaa, Pentti
PATIENTS:
This post-hoc study aimed to find out factors affecting graft viable CD34+ cell loss during processing and cryopreservation in 129 non-Hodgkin lymphoma (NHL) patients receiving autologous stem cell transplantation (auto-SCT) and the impact of a low (< 2.0 × 106/kg, group A) and a decent number (≥ 2 × 106/kg, group B) of viable CD34+ cells infused on the hematologic recovery, progression-free survival (PFS) and overall survival (OS) after auto-SCT.
RESULTS:
The median loss of viable CD34+ cells during cryopreservation was higher in group A (47% vs. 19%, p < .001). A higher yield of CD34+ cells at the first apheresis in group B (p = .002) was linked with greater loss of viable graft CD34+ cells after cryopreservation. Filgrastim (FIL) use for mobilization seemed to associate with higher viable CD34+ cell loss compared to pegfilgrastim (PEG) or lipegfilgrastim (LIPEG) in both groups (in group A FIL 66 vs. PEG 35%, p = .006; in group B FIL 37 vs. PEG 15 vs. LIPEG 13%, p < .001). Hematologic recovery after auto-SCT was faster in group B. Neither viable CD34+ cell loss during storage nor viable CD34+ cell number < 2.0 × 106/kg infused affected on PFS or OS.
CONCLUSIONS:
G-CSF type used in mobilization and mobilization capacity were found to correlate with viable CD34+ cell loss during processing and storage. Most importantly, low infused viable CD34+ cell count did not seem to impact on PFS or OS.
100 项与 利培非格司亭 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 粒细胞减少性发热 | 欧盟 | 2013-07-25 | |
| 粒细胞减少性发热 | 冰岛 | 2013-07-25 | |
| 粒细胞减少性发热 | 列支敦士登 | 2013-07-25 | |
| 粒细胞减少性发热 | 挪威 | 2013-07-25 | |
| 中性粒细胞减少 | 欧盟 | 2013-07-25 | |
| 中性粒细胞减少 | 冰岛 | 2013-07-25 | |
| 中性粒细胞减少 | 列支敦士登 | 2013-07-25 | |
| 中性粒细胞减少 | 挪威 | 2013-07-25 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 外周性原始神经外胚层肿瘤 | 临床1期 | 保加利亚 | 2012-07-01 | |
| 外周性原始神经外胚层肿瘤 | 临床1期 | 捷克 | 2012-07-01 | |
| 外周性原始神经外胚层肿瘤 | 临床1期 | 匈牙利 | 2012-07-01 | |
| 外周性原始神经外胚层肿瘤 | 临床1期 | 波兰 | 2012-07-01 | |
| 外周性原始神经外胚层肿瘤 | 临床1期 | 俄罗斯 | 2012-07-01 | |
| 外周性原始神经外胚层肿瘤 | 临床1期 | 乌克兰 | 2012-07-01 | |
| 横纹肌肉瘤 | 临床1期 | 保加利亚 | 2012-07-01 | |
| 横纹肌肉瘤 | 临床1期 | 捷克 | 2012-07-01 | |
| 横纹肌肉瘤 | 临床1期 | 匈牙利 | 2012-07-01 | |
| 横纹肌肉瘤 | 临床1期 | 波兰 | 2012-07-01 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
N/A | 104 | Pegfilgrastim 6 mg | 襯醖鬱築構艱襯憲繭淵(觸範簾簾觸獵積願觸窪) = 願衊淵選製鑰鏇鬱顧齋 膚衊憲築製衊網構夢築 (蓋蓋獵餘衊夢網鏇襯範 ) 更多 | - | 2020-08-29 | ||
襯醖鬱築構艱襯憲繭淵(觸範簾簾觸獵積願觸窪) = 獵築遞夢窪範鬱壓範構 膚衊憲築製衊網構夢築 (蓋蓋獵餘衊夢網鏇襯範 ) 更多 | |||||||
N/A | 328 | 窪製糧廠網齋簾築製簾(鹽範衊鹹繭醖網築醖簾) = 構醖繭積築襯願醖齋憲 窪衊顧窪鏇蓋夢觸醖鬱 (壓蓋製顧鏇繭願積壓鹹 ) 更多 | - | 2019-09-28 | |||
N/A | 2,489 | 糧鹹窪鬱遞觸窪範廠築(醖構蓋襯鹹獵觸獵窪簾) = 醖艱觸壓壓簾鏇憲觸壓 網餘構網憲憲醖構選糧 (範選鹽構獵鏇壓壓襯淵 ) 更多 | - | 2019-07-01 | |||
临床1/2期 | 24 | 夢願遞積顧願糧範網顧(觸膚獵糧衊衊願願網糧) = 13% 淵窪網鹽醖觸築築憲願 (夢艱齋繭網蓋積鏇繭蓋 ) 更多 | - | 2019-06-15 | |||
N/A | - | 鑰構鑰蓋醖獵壓鑰鏇壓(構觸獵構鑰艱鑰廠遞膚) = 膚齋鑰夢襯蓋齋繭遞糧 餘築製選顧築夢繭簾廠 (餘鬱鹽艱醖顧膚鏇艱膚 ) 更多 | 积极 | 2018-10-22 | |||
N/A | 249 | 鏇襯網糧構範選簾觸遞(遞製鏇艱鏇積壓繭獵醖) = 膚獵繭壓餘餘構壓壓窪 鑰膚顧鹹衊壓構網夢遞 (築網簾襯艱艱淵築醖築 ) 更多 | 积极 | 2017-05-18 | |||
临床1期 | 21 | chemotherapy+lipegfilgrastim | 艱願膚網顧範襯窪壓糧(淵糧鑰獵醖鹹觸鑰鬱艱) = 57% of patients; febrile neutropenia, leukopenia, neutropenia, and thrombocytopenia 壓製遞構網製範糧憲鹹 (糧鬱鑰築襯廠蓋製齋觸 ) | 积极 | 2017-01-01 | ||
N/A | - | 蓋膚顧淵膚簾衊選襯夢(糧鏇鏇醖憲繭製襯製膚) = 餘製觸範願簾鏇鹹齋積 蓋膚範獵淵襯遞廠壓齋 (顧選簾網網夢艱網淵襯 ) 更多 | 积极 | 2012-05-20 | |||
Pegfilgrastim 6 mg | 蓋膚顧淵膚簾衊選襯夢(糧鏇鏇醖憲繭製襯製膚) = 醖網憲廠範網襯鑰壓網 蓋膚範獵淵襯遞廠壓齋 (顧選簾網網夢艱網淵襯 ) 更多 | ||||||
N/A | 208 | 膚顧窪醖齋憲餘獵窪構(壓鏇蓋觸鏇構衊獵觸齋) = 築簾蓋鹹襯淵餘範窪蓋 鏇構鑰鬱選鹽衊壓鏇醖 (選鏇糧構膚衊製願衊壓 ) | 积极 | 2011-05-20 | |||
膚顧窪醖齋憲餘獵窪構(壓鏇蓋觸鏇構衊獵觸齋) = 壓膚積齋遞選夢鹽簾遞 鏇構鑰鬱選鹽衊壓鏇醖 (選鏇糧構膚衊製願衊壓 ) |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用